research Structure of human steroid 5α-reductase 2 with anti-androgen drug finasteride
The research helps understand how finasteride works and aids drug development.
Search
for
Sort by
Research
900-930 / 1000+ results
research Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta
Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
research Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production
A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
research Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
research Insights into the peripheral nature of persistent sexual dysfunction associated with post-finasteride, post-SSRI and post-accutane syndromes: lessons learned from a case study
Peripheral treatments showed some improvement in sexual dysfunction, but central symptoms remain challenging.
research Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Dutasteride 0.5mg is more effective than finasteride 1mg for treating male pattern baldness.
research A Case of Unilateral Idiopathic Gynecomastia Aggravated by Low-dose Finasteride (1mg/day, Propecia$^{(R)}$)
Low-dose finasteride can cause painful breast enlargement in men, which resolves after stopping the medication.
research Konvergentna validacija farmakoekonomskih aspekata terapije benigne hiperplazije prostate u Crnoj Gori
Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
research 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5α-reductase inhibitors may lower the risk of death from bladder cancer.
research Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies
The herbal combination of saw palmetto and stinging nettle reduces nighttime urination in men with urinary issues.
research Cost-minimization Analysis of 2 Drug Therapy Projects Including Traditional Chinese Medcines and Chemical Medcines in BPH Patients
Qianliekang and liuweidihuangwan are cheaper for BPH treatment than finasteride and tamsulosin.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
Dutasteride safely treats hair loss without harming sexual function.
research Effect of Low-Dose Finasteride on Serum PSA Concentrations
Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
research Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States
Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
research Price discrimination across indications in the pharmaceutical industry: The case of finasteride
The same drug is priced differently based on its use.
research Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors
Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.
research Pharmacokinetics and Bioequivalence of Finasteride Tablets in Healthy Subjects
The two finasteride tablet formulations are bioequivalent.
research 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (vol 35, pg e243, 2021)
Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
research Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
The document did not conclude on apremilast's effectiveness for severe alopecia areata.
research 133 Grey-Scale Penile Ultrasound Findings in Young Men with Erectile Dysfunction (ED) Who Used Finasteride for Androgenic Alopecia: A Retrospective Review
Finasteride for hair loss can cause erectile dysfunction due to tissue fibrosis.
research 17β-Estradiol Enhances Vascular Endothelial Growth Factor Production and Dihydrotestosterone Antagonizes the Enhancement via the Regulation of Adenylate Cyclase in Differentiated THP-1 Cells
Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
research PSA Test Sensitized by Finasteride
Finasteride improves prostate cancer detection in PSA test.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research Novel tip-loaded dissolving and implantable microneedle array patches for sustained release of finasteride
New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.
research Preparation of novel polymeric microspheres for controlled release of finasteride
PPCM microspheres allow controlled finasteride release over 24 hours.
research Urticarial rush due to finasteride
Finasteride can cause skin rash.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.